Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to antracycline/CMF-based chemotherapy.

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy / D. Coradini, E. Biganzoli, I. Ardoino, F. Ambrogi, P. Boracchi, R. Demicheli, M.G. Daidone, A. Moliterni. - In: THE BREAST. - ISSN 0960-9776. - 24:3(2015 Jun), pp. 294-297. [10.1016/j.breast.2015.01.007]

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy

E. Biganzoli
Secondo
;
I. Ardoino;F. Ambrogi;P. Boracchi;
2015

Abstract

Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to antracycline/CMF-based chemotherapy.
Breast cancer; Triple negative; p53 status; Adjuvant chemotherapy
Settore MED/01 - Statistica Medica
Settore MED/06 - Oncologia Medica
giu-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0960977615000089-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 412.57 kB
Formato Adobe PDF
412.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/285893
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact